Mass Spectrometry–Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma
Carlo Martins, Sarah Huet, San San Yi et al. · Journal of Molecular Diagnostics · 2020
Cited by 39 works. doi:10.1016/j.jmoldx.2020.04.002 Open-access PDF
Authors
References
- Cancer statistics, 2016
- Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MS
- Skyline: an open source document editor for creating and analyzing targeted proteomics experiments
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
- Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma
- IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities
- Antibody therapeutics: